Table 2.

Estimates of treatment effect on the primary outcome measured by WHO 7-point ordinal scale on day 29 after randomisation

	Placebo (n=214)	Brensocatib (n=190)	Model	Effect size (95% CI)	p value
Not hospitalised and no limitations on activities	40 (19%)	28 (15%)	Unadjusted	0·74 (0 ·50–1 ·09)	..
Not hospitalised and limitations on activities	129 (60%)	112 (59%)	Adjusted*	0·72 (0 ·57–0 ·92)	0·0077
Hospitalised and not requiring supplemental oxygen	11 (5%)	7 (4%)	..	..	..
Hospitalised and requiring supplemental oxygen	1 (0%)	6 (3%)	..	..	..
Hospitalised and on non-invasive ventilation or high flow oxygen devices	1 (0%)	0	..	..	..
Hospitalised and on invasive mechanical ventilation or extracorporeal membrane oxygenation	6 (3%)	5 (3%)	..	..	..
Death	23 (11%)	29 (15%)	..	..	..
Lost to follow-up	3 (1%)	3 (1%)	..	..	..

Data are n (%) unless otherwise specified.

^*Adjusted for minimisation variables, age and site (using clustered SEs).